Orchestra Biomed Hldgs Inc (OBIO)

$3.11 +0.10 (3.32%)
Market Cap 115.32M
Revenue (ttm) 2.64M
Net Income (ttm) -61.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,311.36%
Debt to Equity Ratio 0.85
Volume 169,749
Avg Vol 511,252
Day's Range N/A - N/A
Shares Out 38.31M
Stochastic %K 17%
Beta 0.64
Analysts Strong Sell
Price Target $13.57

Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications;...

Industry: Biotechnology
Sector: Healthcare
Phone: 215 862 5797
Address:
150 Union Square Drive, New Hope, United States
daus12
daus12 Jun. 18 at 6:40 PM
$OBIO don’t forget its still a pos stock😄
0 · Reply
daus12
daus12 Jun. 18 at 1:44 PM
$OBIO
0 · Reply
eigthman1
eigthman1 Jun. 18 at 12:12 PM
$OBIO stock is now fully broken above it's 50-day moving average. This one looks very inviting to me. I think it's got to move to at least the 200-day moving average. I'm a buyer today
0 · Reply
brodobagginz
brodobagginz Jun. 16 at 5:35 PM
$OBIO i think i'm fading this one - I'm still red but I can't wait on it any longer, I'm so done w this ticker.
0 · Reply
Viiinnkkaa
Viiinnkkaa Jun. 16 at 1:16 PM
$OBIO up 7% in pre
0 · Reply
The1Albatross
The1Albatross Jun. 12 at 10:24 PM
$OBIO What can happen here is uncanny tbo. Folks need to learn about this play asap
1 · Reply
BigRodddd
BigRodddd Jun. 9 at 7:32 PM
$OBIO
0 · Reply
Ferg500
Ferg500 Jun. 9 at 4:02 PM
$OBIO
0 · Reply
LebronBOOM
LebronBOOM Jun. 9 at 3:38 PM
$OBIO Green now
0 · Reply
Fearrr
Fearrr Jun. 9 at 3:36 PM
$OBIO
0 · Reply
Latest News on OBIO
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Jun 18, 2025, 9:30 AM EDT - 5 days ago

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28, 2025, 7:20 AM EDT - 26 days ago

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025, 4:28 PM EDT - 5 weeks ago

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025, 8:30 AM EDT - 6 weeks ago

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Apr 29, 2025, 9:00 AM EDT - 7 weeks ago

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Apr 28, 2025, 4:30 PM EDT - 7 weeks ago

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Apr 23, 2025, 9:00 AM EDT - 2 months ago

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

MDT

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Apr 22, 2025, 7:00 AM EDT - 2 months ago

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Mar 31, 2025, 4:21 PM EDT - 2 months ago

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Orchestra BioMed to Present at Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 4 months ago

Orchestra BioMed to Present at Upcoming Investor Conferences

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Feb 18, 2025, 8:00 AM EST - 4 months ago

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Feb 12, 2025, 10:43 AM EST - 4 months ago

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Feb 5, 2025, 8:00 AM EST - 4 months ago

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:05 PM EST - 7 months ago

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 4:12 PM EST - 7 months ago

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 12, 2024, 4:20 PM EDT - 11 months ago

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 8:43 AM EDT - 1 year ago

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:58 PM EDT - 1 year ago

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Mar 27, 2024, 4:17 PM EDT - 1 year ago

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Orchestra BioMed to Participate in Upcoming Investor Conferences

Mar 7, 2024, 8:00 AM EST - 1 year ago

Orchestra BioMed to Participate in Upcoming Investor Conferences

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Mar 6, 2024, 8:37 AM EST - 1 year ago

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Jan 8, 2024, 7:30 AM EST - 1 year ago

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 4:21 PM EST - 1 year ago

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Sep 19, 2023, 7:30 AM EDT - 1 year ago

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:34 PM EDT - 2 years ago

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Jun 7, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 9:15 AM EDT - 2 years ago

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Feb 24, 2023, 8:00 AM EST - 2 years ago

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Jan 27, 2023, 8:00 AM EST - 2 years ago

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

Jul 5, 2022, 8:00 AM EDT - 3 years ago

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

daus12
daus12 Jun. 18 at 6:40 PM
$OBIO don’t forget its still a pos stock😄
0 · Reply
daus12
daus12 Jun. 18 at 1:44 PM
$OBIO
0 · Reply
eigthman1
eigthman1 Jun. 18 at 12:12 PM
$OBIO stock is now fully broken above it's 50-day moving average. This one looks very inviting to me. I think it's got to move to at least the 200-day moving average. I'm a buyer today
0 · Reply
brodobagginz
brodobagginz Jun. 16 at 5:35 PM
$OBIO i think i'm fading this one - I'm still red but I can't wait on it any longer, I'm so done w this ticker.
0 · Reply
Viiinnkkaa
Viiinnkkaa Jun. 16 at 1:16 PM
$OBIO up 7% in pre
0 · Reply
The1Albatross
The1Albatross Jun. 12 at 10:24 PM
$OBIO What can happen here is uncanny tbo. Folks need to learn about this play asap
1 · Reply
BigRodddd
BigRodddd Jun. 9 at 7:32 PM
$OBIO
0 · Reply
Ferg500
Ferg500 Jun. 9 at 4:02 PM
$OBIO
0 · Reply
LebronBOOM
LebronBOOM Jun. 9 at 3:38 PM
$OBIO Green now
0 · Reply
Fearrr
Fearrr Jun. 9 at 3:36 PM
$OBIO
0 · Reply
DarcyF
DarcyF Jun. 9 at 3:28 PM
$OBIO "Secured ten new fully-issued patents related to hypertension treatment during last 12 months"
0 · Reply
IsaacP2
IsaacP2 Jun. 9 at 3:11 PM
$OBIO These guys have 137 patents around their Treatment of Hypertension and Heart Failure
0 · Reply
StocksPlusStuffers
StocksPlusStuffers Jun. 9 at 3:04 PM
$OBIO
0 · Reply
RandomlySelected
RandomlySelected Jun. 9 at 3:02 PM
$OBIO Over that $3 wall
0 · Reply
Stoness5687
Stoness5687 Jun. 9 at 2:31 PM
$OBIO Need some more news!!
0 · Reply
Fidely
Fidely Jun. 9 at 2:10 PM
$OBIO
0 · Reply
Fearrr
Fearrr Jun. 6 at 2:57 PM
$OBIO
0 · Reply
BigRodddd
BigRodddd Jun. 6 at 2:56 PM
$OBIO
0 · Reply
OptimistFrank851
OptimistFrank851 Jun. 6 at 2:53 PM
$OBIO
0 · Reply
StocksPlusStuffers
StocksPlusStuffers Jun. 6 at 2:37 PM
$OBIO "We believe the FDA’s Breakthrough Device Designation for AVIM therapy signals meaningful recognition of its potential to meet the clinical needs of millions living with hypertensive heart disease"
0 · Reply
PaoloWorld
PaoloWorld Jun. 6 at 2:34 PM
$OBIO
0 · Reply
Stoness5687
Stoness5687 Jun. 6 at 2:31 PM
$OBIO 'Research and development expenses for the first quarter of 2025 were $13.5 million'
0 · Reply